Dr Corinne Ramos

Corinne Ramos received a Ph.D. in Molecular Biology from the University Paul Sabatier (Toulouse, France) and an MBA from the Johns Hopkins University-Carey Business School (Washington DC, USA).
She has worked extensively on the identification and development of biomarkers to predict therapeutic outcomes.  Corinne Ramos joined ImaBiotech in 2020 as the Director of Innovation and Marketing with the responsibility to support the innovative research and boost the strategic sales business position of Aliri (formerly Imabiotech).

Her areas of expertise are:

  • Clinical Assay/Biomarker Development Validation
  • Molecular Oncology and Imaging in Oncology/Diagnostics

With more than 20 years of experience leading innovative research and clinical programs, Corinne is known for driving clinical development to successful commercialization. Her operational experience includes overseeing R&D, product development and clinical laboratory operations centered on CLIA waived molecular diagnostics. She has published 35 publications with the recent one being on Phosphoproteomic analysis of matched primary breast cancer (BC) and lymph node (LN) metastases.

Dr. David Bonnel

David Bonnel received a Ph.D. in Biology from the CNRS (Lille, France) and a Ph.D. in Biochemistry from the Institute of Pharmacology of Sherbrooke (Sherbrooke, Canada). He worked and published on the development and applications of mass spectrometry imaging (MSI) in the fields of health and pharmacology, more specifically in Oncology and biomarkers research, with Pr Isabelle Founier and Pr. Michel Salzet (pioneers in Europe in MSI). Dr. Bonnel joined ImaBiotech in 2010 to install the platforms and develop the analytical approaches. After being in charge of more than 300 studies during 10 years, he has been named Director of Operations and then Executive Director of the French site. Dr. Bonnel manages the business unit and supervises all the scientific activities and strategical development of Aliri (formerly ImaBiotech) in Europe. His expertise area are:

  • Pharma small molecule development
  • In situ Pharmacokinetics and pharmacodynamics
  • Molecular histology and imaging dedicated to the biotech and pharmaceutical developments

Over the last 10 years, Dr. Bonnel has been in charge of the design, submission and realization of several national and European grants at ImaBiotech with different consortia (FP7-HiPAD, FP7-CarTarDis,  Interreg-IMODE and  recently IMI-ERA4TB)

Since 2018, Dr. Bonnel is also member of the NHL Cluster, a French competitiveness cluster designed to stimulate and support collaborative research between private companies and academic laboratories in projects at the crossroads of biotechnology and health.